



Unifying the care experience

APPENDIX 4E
PRELIMINARY FINAL
REPORT
YEAR ENDED
31 DECEMBER 2020



Appendix 4E

Preliminary Final Report

Oneview Healthcare PLC

ABN 610 611 768

1. Company Details

Name of Entity

Oneview Healthcare PLC

ABN or equivalent
company reference

610 611 768

Financial year ended
(current period)

31 December 2020

Financial year ended
(previous period)

31 December 2019

2. Results for announcement to the market

	Up/down	% change	31 December 2020 €'000	31 December 2019 €'000
Recurring revenue from ordinary activities	Up	13%	5,108	4,528
Total revenue from ordinary activities	Up	0%	7,102	7,098
(Loss) from ordinary activities after tax attributable to members (including significant items)	Down	44%	(9,454)	(16,941)
(Loss) from ordinary activities after tax attributable to members (excluding significant items *)	Down	51%	(8,238)	(16,972)

* Significant items incurred include FX and non-cash share based payments.

3. Net Tangible Assets Per Security

	31 December 2020 €	31 December 2019 €
Net Tangible Assets Per Security	0.01	0.04

Net tangible assets are defined as the net assets of Oneview Healthcare PLC less intangible assets. A small proportion of the Company's assets are intangible in nature. These assets are excluded from the calculation of net tangible assets per security shown above.

4. Commentary on Results

The principal activity of the Group is the development and sale of software for the healthcare and aged care sectors and the provision of related consultancy services.

The directors report that revenue for the year from continuing operations amounted to €7,101,982 (2019: €7,097,701), an increase of 0.1%. Recurring revenue for the year amounted to €5,107,783 (2019: €4,527,548), an increase of 13% and continues to grow as the company deploys across its customer base.

During the year, the Company successfully conducted a conditional placement which raised A\$8.7 million before costs. The net proceeds of these issues will be used to accelerate cloud development of the Group's Care Experience Platform, invest in sales and marketing across the US and Australia and provide working capital to strengthen the Company's balance sheet to support growth.

As at 31 December 2020, the Oneview Inpatient solution was live in 9,259 beds with a further 2,555 beds contracted but not yet installed.

The Company continues to carefully control expenses and has managed a reduction in full time headcount from 109 at the beginning of the year to 71 at 31 December 2020.

5. Dividends

The Company has not declared, and does not propose to pay, any dividends for the year ended 31 December 2020 (31 December 2019: Nil). There are no dividend or dividend reinvestment plans in operation.

6. Details of entities over which control has been gained or lost during the period

There are no entities over which control has been gained or lost in the period.

7. Associates and joint venture entities

There are no associate or joint venture entities.

8. Audit status

This Appendix 4E and the included financial information are based on financial statements which are in the process of being audited.

9. Foreign entity accounting standards

The Financial Statements contained within the Preliminary Final Report are measured and recognised in accordance with International Financial Reporting Standards, as adopted by the European Union.

10. Financial Report

The following financial report included in this Appendix 4E does not include all notes of the type normally included within the annual financial report and therefore cannot be expected to provide as full an understanding of the financial performance, financial position and operating, financial and investing activities of the consolidated entity as the full financial report. The financial report should be read in conjunction with any public announcements made by Oneview Healthcare PLC in accordance with the continuous disclosure obligations of the ASX Listing Rules.

The accounting policies are the same as those applied in the most recent interim financial report and the previous annual report.

Consolidated Statement of Total Comprehensive Income

for the year ended 31 December 2020

		2020 Unaudited	2019 Audited
	Note	€	€
Revenue - continuing operations	2	7,101,982	7,097,701
Cost of sales		(2,378,489)	(2,838,185)
Gross profit		4,723,493	4,259,516
Sales and marketing expenses		(1,562,533)	(4,290,333)
Product development and delivery expenses		(7,326,700)	(12,036,302)
General and administrative expenses		(3,430,783)	(4,708,796)
Restructuring expenses		(1,150,654)	-
Operating loss		(8,747,177)	(16,775,915)
Finance charges		(636,345)	(110,324)
Finance income		267	49,460
Loss before tax		(9,383,255)	(16,836,779)
Income tax		(71,208)	(104,376)
Loss for the year		(9,454,463)	(16,941,155)
Attributable to ordinary shareholders		(9,454,463)	(16,941,155)
<i>Loss per share</i>			
Basic	3	(0.05)	(0.12)
Diluted	3	(0.05)	(0.12)
Other comprehensive loss			
<i>Items that will or may be reclassified to profit or loss:</i>			
Foreign currency translation differences on foreign operations (no tax impact)		315,109	(5,431)
Other comprehensive loss, net of tax		315,109	(5,431)
Total comprehensive loss for the year		(9,139,354)	(16,946,586)

The total comprehensive loss for the year is entirely attributable to equity holders of the Group.

Consolidated Statement of Financial Position

as at 31 December 2020

		2020 Unaudited	2019 Audited
	Note	€	€
Non-current assets			
Intangible assets	4	699,325	768,822
Property, plant and equipment	5	1,649,840	1,993,345
Research and development tax credit	6	636,317	620,479
Total non-current assets		2,985,482	3,382,646
Current assets			
Inventories		236,633	235,319
Trade and other receivables	6	3,964,480	3,519,224
Contract assets		248,766	348,666
Current income tax receivable		7,116	18,180
Cash and cash equivalents		6,804,367	10,262,820
Total current assets		11,261,362	14,384,209
Total assets		14,246,844	17,766,855
Equity			
Issued share capital	8	394,589	175,288
Share premium	8	106,785,298	101,630,025
Treasury reserve		(2,586)	(2,586)
Other undenominated capital		4,200	4,200
Translation reserve		267,212	(47,897)
Reorganisation reserve		(1,351,842)	(1,351,842)
Share based payments reserve		3,813,324	3,467,957
Retained earnings		(105,841,482)	(96,196,006)
Total equity		4,068,713	7,679,139
Non-current liabilities			
Lease liabilities		1,088,295	1,499,310
Deferred income		271,249	394,518
Total non-current liabilities		1,359,544	1,893,828
Current liabilities			
Trade and other payables	7	8,336,632	7,952,171
Lease liabilities		423,755	241,717
Current income tax liabilities		58,200	-
Total current liabilities		8,818,587	8,193,888
Total liabilities		10,178,131	10,087,716
Total equity and liabilities		14,246,844	17,766,855

Consolidated Statement of Cash Flows

for the year ended 31 December 2020

		2020 Unaudited	2019 Audited
	Note	€	€
Cash flows from operating activities			
Receipts from customers		7,287,224	10,853,747
Payments to suppliers		(6,060,301)	(8,273,765)
Payments to employees and consultants		(9,959,092)	(15,616,634)
Finance charges paid		(13,540)	(18,595)
Interest received		267	774
Research and development tax credit received		1,040,337	-
Income tax refunded/(paid)		12,826	(107,381)
Net cash used in operating activities	9	(7,692,279)	(13,161,854)
Cash flows from investing activities			
Purchase of property, plant and equipment	5	(49,584)	(122,668)
Proceeds on disposal of property, plant and equipment		-	10,120
Acquisition of intangible assets	4	(199,771)	(308,077)
Net cash used in investing activities		(249,355)	(420,625)
Cash flows from financing activities			
Proceeds from issue of shares		5,374,574	15,906,961
Transaction costs		(245,523)	(1,226,159)
Repayment of loan by former director		252,469	-
Repayment of lease liabilities		(432,038)	(279,041)
Net cash provided by financing activities		4,949,482	14,401,761
Net increase/(decrease) in cash held		(2,992,152)	819,282
Foreign exchange impact on cash and cash equivalents		(466,301)	112,590
Cash and cash equivalents at beginning of financial year		10,262,820	9,330,948
Cash and cash equivalents at end of financial year		6,804,367	10,262,820

Consolidated Statement of Changes in Equity

as at 31 December 2020

	Share capital	Share premium	Treasury reserve	Other undenominated capital	Reorganisation reserve	Share based payments reserve	Translation reserve	Retained loss	Total equity
	€	€	€	€	€	€	€	€	€
Balance at 1 January 2019	69,546	85,828,481	(2,586)	4,200	(1,351,842)	5,911,172	(42,466)	(80,489,997)	9,926,508
Loss for the year	-	-	-	-	-	-	-	(16,941,155)	(16,941,155)
Foreign currency translation	-	-	-	-	-	-	(5,431)	-	(5,431)
Total comprehensive loss	-	-	-	-	-	-	(5,431)	(16,941,155)	(16,946,586)
<i>Transactions with</i>									
Issue of ordinary shares	103,350	15,801,544	-	-	-	-	-	(1,226,159)	14,678,735
Share based compensation	-	-	-	-	-	18,090	-	-	18,090
Exercise of options	2,392	-	-	-	-	(2,259,733)	-	2,259,733	2,392
Transfer to retained earnings in respect of expired options	-	-	-	-	-	(201,572)	-	201,572	-
As at 31 December 2019	175,288	101,630,025	(2,586)	4,200	(1,351,842)	3,467,957	(47,897)	(96,196,006)	7,679,139
Balance at 1 January 2020	175,288	101,630,025	(2,586)	4,200	(1,351,842)	3,467,957	(47,897)	(96,196,006)	7,679,139
Loss for the year	-	-	-	-	-	-	-	(9,454,463)	(9,454,463)
Foreign currency translation	-	-	-	-	-	-	315,109	-	315,109
Total comprehensive loss	-	-	-	-	-	-	315,109	(9,454,463)	(9,139,354)
<i>Transactions with</i>									
Issue of ordinary shares	219,211	5,155,273	-	-	-	-	-	(563,497)	4,810,987
Share based compensation	-	-	-	-	-	717,851	-	-	717,851
Exercise of options	90	-	-	-	-	(363,330)	-	363,330	90
Transfer to retained earnings in respect of expired options	-	-	-	-	-	(9,154)	-	9,154	-
As at 31 December 2020	394,589	106,785,298	(2,586)	4,200	(1,351,842)	3,813,324	267,212	(105,841,482)	4,068,713

1. Statement of Significant Accounting Policies

Statement of compliance

This report is not a set of statutory financial statements and does not include all the information required for a complete set of financial statements, prepared in accordance with IFRS as adopted by the European Union. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group's financial position and performance since 31 December 2019. They should be read in conjunction with the statutory consolidated financial statements of the Group, which were prepared in accordance with IFRS as adopted by the European Union, as at and for the year ended 31 December 2019 and also in conjunction with any public announcements made by Oneview Healthcare PLC during the year.

Going Concern

The Group's financial statements have been prepared and presented on a going concern basis.

This report adopts the going concern basis of accounting, which contemplates the realisation of assets and the discharge of liabilities and commitments in the ordinary course of business.

The Directors believe the business has adequate levels of working capital to fund the Group's strategic goals. They believe, therefore, that the Group continues to be a going concern and that it will be able to pay its debts as and when they fall due, for a period of at least 12 months from the date of this report.

On this basis, the Directors believe that the going concern basis of presentation is appropriate. No adjustments have been made relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Group not have the ability to continue as a going concern. If for any reason the Group is unable to continue as a going concern, it would impact on the Group's ability to realise assets at their recognised values and to extinguish liabilities in the normal course of business at the amounts stated in the consolidated financial statements.

Use of estimates and judgments

The preparation of financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected. In preparing this financial report, the significant judgments made by management in applying the Group's accounting policies and the key sources of estimation and uncertainty were the same as those that apply to the consolidated financial statements for the year ended 31 December 2019.

Notes to the Preliminary Final Report

for the year ended 31 December 2020

2. Segmental Information

Revenue by type

Recurring revenue:	2020	2019
	€	€
Software usage and content	3,298,665	2,922,680
Support income	1,353,456	1,273,322
Licence fee	455,662	331,546
	5,107,783	4,527,548
Non-recurring revenue:		
Hardware	1,218,797	1,096,806
Services income	775,402	1,473,347
	1,994,199	2,570,153
Total revenue	7,101,982	7,097,701

Revenue attributable to geographic region:	2020	2019
	€	€
Ireland	4,699	5,529
Europe (excluding Ireland)	-	17,515
United States	3,428,979	3,313,946
Australia	3,074,241	3,280,925
Asia	423,440	323,990
Middle East and North Africa	170,623	155,796
Total revenue	7,101,982	7,097,701

3. Earnings per share

	2020	2019
	€	€
Basic earnings per share		
Loss attributable to ordinary shareholders	(9,454,464)	(16,941,155)
Weighted average number of ordinary shares Outstanding (i)	186,248,903	135,711,700
Basic loss per share	(0.05)	(0.12)

Notes to the Preliminary Final Report
for the year ended 31 December 2020

3. Earnings per share (continued)

	2020 No.	2019 No.
(i) Weighted-average number of ordinary shares (basic)		
Issued ordinary shares at 1 January	175,287,233	69,545,563
Effect of shares issued	10,961,670	66,166,137
Weighted average number of ordinary shares at 31 December	<u>186,248,903</u>	<u>135,711,700</u>

Basic loss per share is calculated by dividing the loss for the year after taxation attributable to ordinary shareholders by the weighted average number of ordinary shares in issue during the year.

	2020 €	2019 €
Diluted earnings per share		
Loss attributable to ordinary shareholders	(9,454,464)	(16,941,155)
Weighted average number of ordinary shares Outstanding (ii)	<u>186,248,903</u>	<u>135,711,700</u>
Diluted loss per share	<u>(0.05)</u>	<u>(0.12)</u>

	2020 No.	2019 No.
(ii) Weighted-average number of ordinary shares (diluted)		
Issued ordinary shares at 1 January	175,287,233	69,545,563
Effect of shares issued	10,961,670	66,166,137
Weighted average number of ordinary shares at 31 December	<u>186,248,903</u>	<u>135,711,700</u>

The calculation of diluted earnings per share has been based on the loss attributable to ordinary shareholders and weighted average number of ordinary shares outstanding after adjustments for the effects of all dilutive ordinary shares. Potential ordinary shares are treated as dilutive when, and only when, their conversion to ordinary shares would decrease EPS or increase the loss per share from continuing operations. As the Group is loss making there is no difference between the basic and diluted earnings per share. The weighted average number of ordinary shares, including potentially dilutive shares, is 199,816,079.

Notes to the Preliminary Final Report
for the year ended 31 December 2020

4. Intangible assets

	Software €	Development costs €	Total €
Cost			
At 1 January 2019	209,646	4,705,899	4,915,545
Additions	-	308,077	308,077
Foreign exchange translation differences	1,916	-	1,916
At 31 December 2019	211,562	5,013,976	5,225,538
At 1 January 2020	211,562	5,013,976	5,225,538
Additions	-	199,771	199,771
Foreign exchange translation differences	(2,925)	-	(2,925)
At 31 December 2020	208,637	5,213,747	5,422,384
Accumulated amortisation and impairment losses			
At 1 January 2019	114,226	3,542,513	3,656,739
Amortisation	82,654	403,484	486,138
Impairment	-	312,777	312,777
Foreign exchange translation differences	1,062	-	1,062
At 31 December 2019	197,942	4,258,774	4,456,716
At 1 January 2020	197,942	4,258,774	4,456,716
Amortisation	16,069	256,124	272,193
Foreign exchange translation differences	(5,850)	-	(5,850)
At 31 December 2020	208,161	4,514,898	4,723,059
Carrying amount			
At 1 January 2019	95,420	1,163,386	1,258,806
At 31 December 2019	13,620	755,202	768,822
At 31 December 2020	476	698,849	699,325

Notes to the Preliminary Final Report
for the year ended 31 December 2020

5. Property, plant and equipment

	Fixtures, fittings and equipment €	Land and Buildings * €	Total €
Cost			
At 1 January 2019	1,449,527	-	1,449,527
Adjustment on initial application of IFRS 16 (note 1)	-	1,216,124	1,216,124
Additions during the year	122,668	735,071	857,739
Disposals during the year	(183,240)	-	(183,240)
Foreign currency translation differences	1,370	-	1,370
At 31 December 2019	1,390,325	1,951,195	3,341,520
At 1 January 2020	1,390,325	1,951,195	3,341,520
Additions during the year	49,584	78,834	128,418
Foreign currency translation differences	(28,322)	(46,382)	(74,704)
At 31 December 2020	1,411,587	1,983,647	3,395,234
Depreciation			
At 1 January 2019	838,686	-	838,686
Charge for the year	261,346	341,498	602,844
Disposals during the year	(94,225)	-	(94,225)
Foreign currency translation differences	870	-	870
At 31 December 2019	1,006,677	341,498	1,348,175
At 1 January 2020	1,006,677	341,498	1,348,175
Charge for the year	157,574	265,900	423,474
Foreign currency translation differences	(20,518)	(5,737)	(26,255)
At 31 December 2020	1,143,733	601,661	1,745,394
Net book value			
At 1 January 2019	610,841	-	610,841
At 31 December 2019	383,648	1,609,697	1,993,345
At 31 December 2020	267,854	1,381,986	1,649,840

Property, plant and equipment is carried at original cost less depreciation and any provision for impairment losses.

* Land and Buildings is comprised of Right of Use assets, held under leases.

Notes to the Preliminary Final Report
for the year ended 31 December 2020

6. Trade and other receivables

	2020 €	2019 €
<i>Amounts falling due within one year:</i>		
Trade receivables	1,813,756	1,226,417
Prepaid expenses and other current assets	1,409,277	853,259
Research and development tax credit	668,086	1,029,850
Sales tax recoverable	73,361	157,229
Loan to key management personnel *	-	252,469
	3,964,480	3,519,224
<i>Amounts falling due after more than one year:</i>		
Research and development tax credit	636,317	620,479
	4,600,797	4,139,703

* Previously reflected as Director's loan in Non-current assets. John Kelly resigned as a director of Oneview Healthcare plc on 4 January 2019. He is a member of the key management personnel team. He repaid the loan in full during the year.

7. Trade and other payables (current)

	2020 €	2019 €
<i>Amounts falling due within one year:</i>		
Trade payables	1,161,786	1,639,488
Payroll related taxes	834,201	222,113
Superannuation / retirement benefit	31,537	67,612
Other payables and accruals	2,720,391	2,122,165
Sales tax payable	149,935	63,594
Deferred income	3,096,546	3,558,573
R&D tax credit – deferred grant income	342,236	278,626
	8,336,632	7,952,171

Notes to the Preliminary Final Report
for the year ended 31 December 2020

8. Share capital

Authorised Share Capital	2020	2019
Ordinary shares		
No. of shares	600,000,000	600,000,000
Nominal value	€0.001	€0.001
"B" Ordinary shares		
No. of shares	420,000	420,000
Nominal value	€0.01	€0.01
	€	€
Authorised Ordinary Shares	600,000	600,000
Authorised "B" Ordinary Shares	4,200	4,200
	<hr/>	<hr/>
Authorised Share Capital	604,200	604,200
	<hr/>	<hr/>

Issued share capital	No of ordinary shares	Par value of units	Share Capital	Share premium	Total
			€	€	€
Balance at 1 January 2019	69,545,563	€0.001 each	69,546	85,828,481	85,898,027
Share issue – 14 May 2019	3,350,000	€0.001 each	3,350	512,193	515,543
Share issue – 16 May 2019	100,000,000	€0.001 each	100,000	15,289,351	15,389,351
Exercise of options – 22 May 2019	2,066,660	€0.001 each	2,067	-	2,067
Exercise of options – 12 Nov 2019	325,000	€0.001 each	325	-	325
	<hr/>	<hr/>	<hr/>	<hr/>	<hr/>
Balance at 31 December 2019	175,287,223	€0.001 each	175,288	101,630,025	101,805,313
Exercise of options – 10 Sept 2020	40,000	€0.001 each	40	-	40
Share issue – 25 Sept 2020	1,176,471	€0.001 each	1,176	-	1,176
Share issue – 24 Nov 2020	43,606,988	€0.001 each	43,607	1,032,577	1,076,184
Exercise of options – 30 Nov 2020	50,000	€0.001 each	50	-	50
Share issue – 18 Dec 2020	174,427,954	€0.001 each	174,428	4,122,696	4,297,124
	<hr/>	<hr/>	<hr/>	<hr/>	<hr/>
Balance at 31 December 2020	394,588,636	€0.001 each	394,589	106,785,298	107,179,887

8. Share capital (continued)

On 11 April 2019, the Company announced to the ASX that it had successfully conducted a Conditional Placement ("Placement") to raise A\$25 million (equivalent to approximately €15.4 million), before costs, through the issue of 100 million CHES depository interests ("CDIs") over new fully paid ordinary shares, subject to the Company obtaining securityholder approval. On the same date, the Company also announced its intention to raise up to A\$2 million by way of a conditional security purchase plan ("SPP"), through the issue of up to 8 million CDIs over new fully paid ordinary shares, subject to the Company obtaining securityholder approval.

On 10 May 2019, the Directors held an Extraordinary General Meeting of the Company where, by special resolution, shareholders voted overwhelmingly to support both the Placement and the SPP. At that meeting, shareholders approved an increase in the authorised ordinary share capital from 100,000,000 ordinary shares of €0.001 each to 600,000,000 ordinary shares of €0.001 each. On the same date, the Company also announced to the ASX that subscriptions had been received from investors for 3,350,000 securities under the SPP. Pursuant to this, on 14 May 2019, the Company issued 3,350,000 new shares of €0.001 each at a price per share of A\$0.25 (equivalent to €0.1539) and on 16 May 2019, the Company issued 100,000,000 new shares of €0.001 each at a price per share of A\$0.25 (equivalent to €0.1539). The Company incurred costs of €1,226,159 associated with the raising of these funds, which have been recorded against retained earnings. The proceeds of these issues will be used to accelerate sales of the inpatient product and to strengthen the balance sheet to facilitate growth.

On 22 May 2019, 2,066,660 ordinary shares were issued in respect of 2,066,660 outstanding share options which were exercised on that date at a strike price of €0.001 per share.

On 12 November 2019, 325,000 ordinary shares were issued in respect of 325,000 outstanding share options which were exercised on that date at a strike price of €0.001 per share.

On 10 September 2020, 40,000 ordinary shares were issued in respect of 40,000 outstanding share options which were exercised on that date at a strike price of €0.001 per share.

On 25 September 2020, 1,176,471 ordinary shares were issued in respect of 1,176,471 restricted share unit awards which vested.

On 18 November 2020, the Company announced to the ASX that it had successfully conducted a conditional placement ("Placement") to raise A\$1.74 million (equivalent to approximately €1.08 million), before costs, through the issue of 43,606,988 CHES depository interests ("CDIs") over new fully paid ordinary shares. On the same date, the Company also announced its intention to raise up to A\$6.98 million by way of a one for one Entitlement Offer, through the issue of up to 174,427,954 CDIs over new fully paid ordinary shares. Pursuant to this, on 24 November 2020, the Company issued 43,606,988 new shares of €0.001 each at a price per share of A\$0.04 (equivalent to €0.0247).

On 30 November 2020, 50,000 ordinary shares were issued in respect of 50,000 outstanding share options which were exercised on that date at a strike price of €0.001 per share.

On 16 December 2020, the Company announced to the ASX it had successfully completed a one for one Entitlement Offer. Pursuant to this, on 18 December 2020, the Company issued 174,427,954 new shares of €0.001 each at a price per share of A\$0.04 (equivalent to €0.0246). The Company incurred costs of €563,497 associated with the raising of the funds from the 2020 Placement and Entitlement Offer, which have been recorded against retained earnings. The proceeds of these issues will be used to accelerate cloud development of the Group's Care Experience Platform, invest in sales and marketing across the US and Australia and provide working capital to strengthen the Company's balance sheet to support growth.

Notes to the Preliminary Final Report
for the year ended 31 December 2020

9. Reconciliation of net cash used in operating activities

	2020 €	2019 €
Loss for the year	(9,454,464)	(16,941,155)
<i>Non-cash items</i>		
Depreciation	423,474	602,844
Loss on disposal of property, plant and equipment	-	78,895
Amortisation of software and development costs	272,193	486,138
Impairment charges	-	312,777
R&D credit, net	(630,801)	(656,967)
Taxation	71,208	104,376
Net finance costs	137,500	109,600
Share based payment expense	717,851	18,090
Foreign exchange loss/(gain)	498,578	(48,691)
Changes in assets and liabilities		
(Increase)/decrease in inventories	(1,314)	436,585
(Increase)/decrease in trade and other receivables	(1,059,489)	62,805
Decrease in contract assets	99,900	1,100,512
(Decrease)/increase in deferred income	(585,296)	978,150
Increase in trade and other payables	778,491	319,389
Cash used in operating activities	(8,732,169)	(13,036,652)
Finance charges paid	(13,540)	(18,595)
Interest received	267	774
Research and development tax credit received	1,040,337	-
Income tax paid	12,826	(107,381)
Net cash used in operating activities	(7,692,279)	(13,161,854)



James Fitter
Chief Executive Officer

Date: 22 February 2021

Corporate Directory

Registered office and business address	Block 2 Blackrock Business Park Carysfort Avenue, Blackrock Co. Dublin Ireland
Independent auditor	KPMG Chartered Accountants 1 Stokes Place St. Stephen's Green Dublin 2
Bankers	HSBC Bank Limited Guildford and Weybridge Commercial Centre Edgeborough Road Guildford Surrey GU12BJ United Kingdom
Solicitors	A&L Goodbody 25-28 North Wall Quay Dublin 1 Clayton Utz Level 15 1 Bligh Street Sydney NSW 2000 Australia
Company secretary	John Kelly (Resigned 4 August 2020) Helena D'Arcy (Appointed 4 August 2020)
Registry	Computershare Investor Services Pty Ltd Level 4 60 Carrington Street Sydney NSW 2000 Australia
Company number	513842
ABRN:	610 611 768
ASX Code:	ASX: ONE
Company Website:	www.oneviewhealthcare.com